RBC's Bri­an Abra­hams holds a mock ad­comm on Bio­gen's iffy ad­u­canum­ab da­ta — and most of these ex­perts don't see a path to an ap­proval

As cat­a­lysts go, few loom larg­er than the ad­u­canum­ab ad­comm slat­ed for Nov. 6.

With its big fran­chise un­der as­sault, Bio­gen is bet­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.